Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Change in Cash (2016 - 2025)

Avanos Medical (AVNS) has disclosed Change in Cash for 13 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 3.21% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.9 million through Dec 2025, down 189.5% year-over-year, with the annual reading at -$17.9 million for FY2025, 189.5% down from the prior year.
  • Change in Cash hit $19.3 million in Q4 2025 for Avanos Medical, up from -$19.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $25.3 million in Q3 2023 to a low of -$32.0 million in Q1 2023.
  • Historically, Change in Cash has averaged -$1.1 million across 5 years, with a median of -$2.6 million in 2021.
  • Biggest five-year swings in Change in Cash: surged 1200.0% in 2022 and later crashed 731.82% in 2023.
  • Year by year, Change in Cash stood at $20.7 million in 2021, then tumbled by 48.31% to $10.7 million in 2022, then tumbled by 281.31% to -$19.4 million in 2023, then soared by 196.39% to $18.7 million in 2024, then rose by 3.21% to $19.3 million in 2025.
  • Business Quant data shows Change in Cash for AVNS at $19.3 million in Q4 2025, -$19.8 million in Q3 2025, and -$6.7 million in Q2 2025.